Roche (RHHBY) said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the extension of the Vabysmo marketing authorisation to include the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. The company expects a final decision from the European Commission in the near future.
The CHMP decision is based on full 72-week data from the Phase III BALATON and COMINO studies evaluating Vabysmo in more than 1,200 people with macular edema due to branch and central RVO.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.